A model of HIV remission is represented by the Post-Treatment Controllers (PTCs) from the Virological and Immunological Sustained CONtrol after Treatment Interruption (VISCONTI) study, who control HIV over 7 years after interrupting combined antiretroviral therapy (cART) initiated shortly after primary HIV-1 infection (PHI) [1, 2] . PTCs and Long-Term-Non-Progressors (LTNPs) display similar magnitude and distribution of their HIV reservoirs, whereas their clinical and genetic backgrounds differ. Indeed, PTCs are frequently HLA-B Ã 35þ, an allele previously associated with symptomatic PHI and rapid progression [3, 4] . Contrarily, they are not enriched in the classical protective HLA-B Ã 27 or B Ã 57 alleles associated with spontaneous HIV control and robust anti-HIV CD8 þ T-cell responses [5] [6] [7] [8] [9] . Accordingly, low levels of HIV-specific CD8 þ T cells producing IFN-g and limited inhibition of HIV production by CD4 þ T cells were previously reported in the VISCONTI PTCs [2] . The impact of HLA alleles was not examined in this study. To further understand whether T-cell-mediated immunity to HIV participated to the exceptional HIV-1 control observed in PTCs, we compared their HIV-specific T-cell responses to those of LTNPs and of Continuously Early-Treated patients (CETs).
We included six HLA-B Ã 35þ and six HLA-B Ã 35À PTCs from the VISCONTI study [2] , who had initiated cART within 10 weeks PHI. All 12 PTCs controlled HIV viremia for a median 3 years after 101-month (75-112) long cART interruption. They were compared with eight treatment-naive LTNPs (ANRS ALT-CO-15 cohort) [10] infected for at least 15 [11] [12] [13] The HIV-specific CD4 þ and CD8 þ T-cells intracellular cytokine-staining assay was performed [14] after stimulation with recombinant HIV-1 p24 (Protein-Sciences, Meriden, Connecticut, USA) or HIV-1 p24 15-mers synthetic peptide pools (Neosystem, Strasbourg, France), respectively. Staining was performed with anti-CD3-Pacific Blue, CD4-ECD (Beckman-Coulter Villepinte, France), CD8-APC-Cy7, IFN-g-Alexa700, IL-2-APC, MIP-1b-FITC, TNFa-PECy7, and CD40L-PE (BDBioscience, San Jose, California, USA) monoclonal antibodies. At least one million cells were analyzed on Gallios Flow-Cytometer with Kaluza 1.2 Software (Beckmann-Coulter). The polyfunctionality index ðPIÞ ¼ P i ¼ 0nFiinq (with q set conservatively to 1) was employed [15] and data were analyzed with the software SPICE (M. Roederer, Immuno Technology Section VRC/NIAID/ NIH, USA) and Funky Cells ToolBox (www.FunkyCells.com). All data were analyzed using the nonparametric Mann-Whitney U test and Spearman's rank test and incorporated Bonferroni corrections for multiple comparisons. All values are medians and interquartile range. (Fig. 1a) . Interestingly, anti-HIV CD4 þ T cells were even more frequent in CETs than in LTNPs [P ¼ 0.013 (NS after Bonferroni correction)], confirming that early cART preserves HIV-specific CD4 þ T cells [11] [12] [13] 16, 17] . In addition, 28.1 and 30.3% HIV-specific CD4 þ T cells from PTCs and CETs, respectively, mediated at least 2 functions, not different from 49% observed in LTNPs, with a similar polyfunctionality index between PTCs, LTNPs, and CETs (30, 35, and 31, respectively) (Fig. 1b) .
The highest HIV-specific CD8 þ T-cell frequencies producing at least one function were observed in LTNPs In contrast, polyfunctional HIV-specific CD8 þ T cells producing at least two functions and polyfunctionality indices tended to be similar in PTCs, LTNPs, and CETs (44.6, 57.5, 47.1% and 33, 32, and 30, respectively) independently of HLA-B Ã 35 (Fig. 1d) . Therefore, despite an HLA-B Ã 35 effect on MIP-1b production, early treatment also appears to preserve functionality of HIV-specific CD8 þ T cells. The importance of robust polyfunctional HIV-specific CD4 þ and CD8 þ T cells is supported by our recent correlation between polyfunctionality and in-vitro cytotoxic capacity [18, 19] , as well as by recent demonstration that T-cell polyfunctionality assessed either using our polyfunctional index or the newly described COMPASS index, predicts protection against HIV acquisition [20] .
Finally, as one infected cell harbors only one HIV-DNA copy, we calculated the 'in-vivo immune effector/target cell ratios' (E/T), by dividing the HIV-specific T cell by the HIV-infected cell numbers per million PBMCs (Fig. 1e and f) [9, 21] . The CD4 E/T ratios [65 (12- Of note, in the small samples studied here, no correlation was observed between the magnitudes and polyfunctionality of HIV-specific CD4 þ and CD8 þ T cells. Whatever the group and after a Bonferroni correction for multiple comparisons, many P values would no longer be statistically significant. Thus, our results, obtained in this small number of samples, strongly suggest the robust polyfunctional anti-HIV CD4 þ T-cell responses preserved by prolonged early cART may have allowed high CD4 E/T ratios in PTCs similarly to LTNPs, and therefore might contribute to virus control, even in HLA-B Ã 35þ individuals. In contrast, CD8 þ T-cell control might not be as contributive because of the HLA-B Ã 35 effect, whereas other mechanisms, such as natural killer cells, might also participate in control of viral reservoirs and in establishment of remission [22] 
